Novo Nordisk's weight-loss drug Wegovy has been approved for long-term weight management in China. The approval by China's National Medical Products Administration, announced on Tuesday via the company's official WeChat account, will allow Novo Nordisk to market Wegovy in the world's second-largest economy, which has the highest number of overweight or obese people. Wegovy, also known as semaglutide, claims to help reduce body weight by 17%, or an average of 16.8 kg. Initially, the company will focus on patients paying out-of-pocket for the weekly injectable drug. This approval is significant as Novo Nordisk faces a tight timeline with its semaglutide patent set to expire soon. Novo Nordisk has also promised to prioritize existing patients amid shortages. The company's shares rose by 1.8% pre-market following the announcement.
Wegovy got approval in China $NVO https://t.co/b9GocvQSP2
Novo Nordisk Shares Hit New Record As Wegovy Gets Approval In China https://t.co/EhAAx8dFA6
Novo Nordisk's weight loss drug Wegovy has been approved in China, the country estimated to have the highest number of overweight or obese people. https://t.co/eUrdoKv5Vb
Novo Nordisk $NVO climbs after Wegovy weight-loss drug reportedly approved in China https://t.co/g9ROOvKpUW https://t.co/zgMLF6ToYM
WATCH: Novo Nordisk's hugely popular weight-loss drug Wegovy has been approved in China — the world's second-largest economy and the country estimated to have the highest number of overweight or obese people https://t.co/8RDLafR8Co https://t.co/CqUh76zno5
$NVO (+1.8% pre) Novo Nordisk's Wegovy weight-loss drug approved in China - Reuters https://t.co/D4uh74815C
China is an open goal for Novo Nordisk’s obesity drug https://t.co/qDJxE3SScP | opinion
A new #obesity drug co-developed by China’s Innovent Biologics Inc. and Eli Lilly & Co. has demonstrated significant #weightloss in a late stage trial, paying the way for its approval in the country to compete with the blockbuster from Novo Nordisk A/S. https://t.co/rAijcbXI87
China offers open goal for Novo Nordisk’s weight loss drug https://t.co/zX8zE7dzNf
Novo Nordisk $NVO said today its weight loss drug Wegovy has been approved in China 🇨🇳 for long-term weight management - CNBC https://t.co/nvvmr6lCV8
Wegovy Approved In China—But Novo Nordisk Promises Existing Patients Priority Amid Shortages https://t.co/cayY56lQs0 https://t.co/k5D4e0SQEh
Novo Nordisk's hugely popular weight-loss drug Wegovy has been approved in China, it said on Tuesday, the world's second-largest economy and the country estimated to hold the highest number of overweight or obese people. https://t.co/Oo3aRpqCbv https://t.co/Oo3aRpqCbv
🇨🇳 WEGOVY WEIGHT-LOSS DRUG APPROVED IN CHINA Initially targeting self-paying Chinese patients, the company has not yet disclosed the start of sales, pricing, or shipment details. Manufacturer, Novo Nordisk faces a tight timeline, with its semaglutide patent set to expire in… https://t.co/b2k4KK7YGM
Novo Nordisk's hugely popular weight-loss drug Wegovy has been approved in China — the world's second-largest economy and the country estimated to have the highest number of overweight or obese people https://t.co/Vp5InJRvoK https://t.co/2o6X6TwyxE
Novo Nordisk’s Wegovy Weight-Loss Drug Gets Approval in China https://t.co/54pBJUqaGV
Novo Nordisk weight loss drug Wegovy approved in China https://t.co/cCool8Lunj
Novo Nordisk’s Wonder Diet Drug Semaglutide Gets Nod to Go to Market in #China @novonordisk https://t.co/I70BoIbxk0
Novo Nordisk's Wegovy weight-loss drug approved in China https://t.co/ZfYij26Bat https://t.co/2zk9yTuIya
Novo Nordisk's Wegovy weight loss drug approved in China https://t.co/M4hGHGOh8S
$NVO | Novo Nordisk’s weight-loss drug Semaglutide, marketed as Wegovy, has been approved in China 🇨🇳 for long-term weight management. Initially, the company will focus on patients paying out-of-pocket for the weekly injectable drug. Novo may have a shorter time in the Chinese… https://t.co/NCgcr5Lze7
Novo Nordisk said its popular weight-loss drug Wegovy has been approved in China, paving the way for its sales in the world's second-largest economy https://t.co/CnCpwE0uvi
Novo Nordisk said its popular weight-loss drug Wegovy has been approved in China, paving the way for its sales in the world's second-largest economy. More here: https://t.co/w5mZCGKCNR
Novo Nordisk's drug Semaglutide has been approved in China for long-term weight management, the company said in a post on an official WeChat account on Tuesday. https://t.co/T0z7TG4Sq7 https://t.co/T0z7TG4Sq7
The National Medical Products Administration approved Novo Nordisk's semaglutide injection Wegovy for chronic weight management for sale in China today. The popular weight loss drug claims to help cut body weight by 17%, or an average of 16.8 kg. @novonordisk https://t.co/Oo5dlXYEDq
⚠️ NOVO NORDISK SEMAGLUTIDE APPROVED FOR LONG-TERM WEIGHT MANAGEMENT IN CHINA - COMPANY STATEMENT
China OKs Novo Nordisk's Type-2 diabetes treatment to enter its market https://t.co/PggCTJuYo4 https://t.co/VaRlssUSIO
⚠️ CHINA'S MEDICAL PRODUCTS AUTHORITY: APPROVES NOVO NORDISK'S TYPE-2 DIABETES TREATMENT TO ENTER THE CHINESE MARKET
Novo Nordisk's popular obesity drug Wegovy helped women with a common heart disease lose more weight than men who had the same condition, an analysis of study data published in a medical journal has shown. https://t.co/2a9vB4S9Wi https://t.co/2a9vB4S9Wi